CN112546120A - Product containing folic acid for relieving anxiety - Google Patents
Product containing folic acid for relieving anxiety Download PDFInfo
- Publication number
- CN112546120A CN112546120A CN202011329674.8A CN202011329674A CN112546120A CN 112546120 A CN112546120 A CN 112546120A CN 202011329674 A CN202011329674 A CN 202011329674A CN 112546120 A CN112546120 A CN 112546120A
- Authority
- CN
- China
- Prior art keywords
- folic acid
- anxiety
- parts
- powder
- relieving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 112
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 69
- 239000011724 folic acid Substances 0.000 title claims abstract description 67
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 67
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 229960000304 folic acid Drugs 0.000 title claims abstract description 62
- 230000036506 anxiety Effects 0.000 title claims abstract description 39
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 63
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 62
- 150000002224 folic acids Chemical class 0.000 claims abstract description 26
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 25
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 25
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 25
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 25
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 24
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 24
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 24
- 244000194101 Ginkgo biloba Species 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 70
- 210000000582 semen Anatomy 0.000 claims description 62
- 241000218628 Ginkgo Species 0.000 claims description 61
- 238000007873 sieving Methods 0.000 claims description 22
- -1 folate compound Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 229940065207 methylfolic acid Drugs 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 8
- 235000008191 folinic acid Nutrition 0.000 claims description 8
- 239000011672 folinic acid Substances 0.000 claims description 8
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 8
- 229960001691 leucovorin Drugs 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 229940014144 folate Drugs 0.000 claims 5
- 229960004793 sucrose Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 235000013305 food Nutrition 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000000949 anxiolytic effect Effects 0.000 abstract description 2
- 230000004630 mental health Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000725 suspension Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000009182 swimming Effects 0.000 description 6
- 206010002869 Anxiety symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 241001336827 Rana chensinensis Species 0.000 description 1
- 241000191896 Rana sylvatica Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of health-care and health-preserving foods, and particularly relates to a folic acid-containing product for relieving anxiety. The folic acid-containing product for relieving anxiety comprises the following components: folic acid compounds, ginkgo leaves, medlar and lotus seeds. The folic acid-containing product for relieving anxiety provided by the invention has the advantages of obvious anxiolytic effect, no toxic or side effect, good taste, suitability for modern people with high pressure and in an anxiety state to eat as leisure food, capability of effectively relieving anxiety of people and benefit for physical and mental health.
Description
Technical Field
The invention belongs to the technical field of health-care and health-preserving foods, and particularly relates to a folic acid-containing product for relieving anxiety.
Background
Anxiety is a basic emotion developed by human beings in the process of adapting to and fighting with the surrounding environment, and is a comprehensive psychological experience of tension and uneasiness presented by the mind when the body presupposes that a certain adverse situation is about to occur.
Anxiety disorder, also known as anxiety neurosis, is characterized primarily by an anxious emotional experience. It can be divided into two forms of chronic anxiety, generalized anxiety and acute anxiety, panic attack. The main performance is as follows: there is no clear and objective object worry about tension, restlessness, and vegetative nerve dysfunction symptoms such as palpitation, hand trembling, sweating, frequent micturition, and exercise restlessness; all of them are normal anxiety, and if the anxiety severity is not consistent with the objective fact or situation, or if the duration is too long, it may be pathological.
At present, anxiety symptoms are mostly treated or relieved by medicines or foods, for example, Chinese patent application CN104207117A discloses a nutritional food for relieving anxiety and a preparation method thereof, which comprises 50 to 150 parts by weight of wood frog eggs, 200 parts by weight of spine date seeds and 50 to 150 parts by weight of mint. The preparation method comprises pulverizing ovum Rana temporaria chensinensis David, semen Ziziphi Spinosae and herba Menthae to 80-100 mesh, and mixing. The positive effects are as follows: the three raw materials are mixed according to a proper proportion to obtain various functional components with different types, wherein the functional components contain unsaturated fatty acid, flavone and volatile oil. The three components are natural food materials, have no toxic or side effect, have food forms, have better patient compliance, and have the advantages of convenient taking, low price and the like. For example, chinese patent application CN111480842A discloses a special medical nutrition formula for anxiety and depression and a preparation method thereof, the formula is as follows: 8-26 parts of protein, 0.005-0.5 part of gamma-aminobutyric acid, 0.2-1 part of folic acid, 0. 12.0005-0.004 part of vitamin B, 0.6-2 parts of vitamin C, 0.002-0.04 part of vitamin E, 0.000001-0.00002 part of vitamin D, 0.01-0.02 part of zinc, 0.2-2 parts of calcium, 0.00005-0.00025 part of selenium, 0.4-1.2 parts of omega-3 fatty acid, 5-20 parts of fat, 0.0026-0.069 part of flavonoid compound, 2-10 parts of new resource food, 4-30 parts of homologous component and 10-25 parts of dietary fiber. The special medical nutrition formula for anxiety and depression provided by the invention can effectively relieve clinical symptoms of anxiety and depression of patients, improve the immunity of organisms, improve the nutritional status of the patients, and play an important role in promoting the functional recovery of nerve cells, eliminating dysphoria, increasing memory and enhancing attention through reasonable diet blending.
Although the prior art has a plurality of products for treating anxiety, the problems still exist, the product has more components or the preparation method is complex, the cost is high, the curative effect is poor, and the like. Therefore, the research on the product for relieving the anxiety, which has the advantages of simple components, concise preparation process, good effect and low cost, has great significance.
Disclosure of Invention
In order to overcome the technical problems, the invention provides a folic acid-containing product for relieving anxiety, which has a good effect of relieving anxiety, is simple in preparation method and is suitable for industrial popularization and application.
In order to achieve the above purpose, the technical scheme provided by the invention is as follows:
a folic acid-containing product for relieving anxiety, which comprises the following components:
folic acid compounds, ginkgo leaves, medlar and lotus seeds.
Preferably, the folic acid compounds are one or more of folic acid, leucovorin, L-methyl folic acid, pharmaceutically acceptable salts of folic acid, active metabolites of folic acid or pharmaceutically acceptable salts of folic acid, and substances metabolized and/or generated in vivo.
Preferably, the folic acid compounds are a mixture of leucovorin and L-methylfolic acid;
preferably, the mass ratio of the leucovorin to the L-methylfolic acid is 1-3: 1; preferably 1: 1;
preferably, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0001-0.001 part of folic acid compound, 5-40 parts of ginkgo leaf, 20-40 parts of medlar and 10-25 parts of lotus seed.
Preferably, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0001-0.0006 part of folic acid compound, 25-40 parts of ginkgo leaf, 20-30 parts of medlar and 10-20 parts of lotus seed.
Preferably, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0001-0.0003 part of folic acid compound, 25-30 parts of ginkgo leaf, 25-30 parts of medlar and 10-15 parts of lotus seed.
Another object of the present invention is to provide a method for preparing the folic acid-containing anxiety-relieving product, which comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, and sieving to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding adjuvants.
Preferably, in the step (1), the sieving is to sieve ginkgo leaves through a sieve of 100-120 meshes, and the medlar and the lotus seeds are respectively sieved through a sieve of 80-100 meshes.
Preferably, in the step (2), the auxiliary material is any one or more of sucrose or xylitol, protein sugar and stevioside.
Preferably, in the step (2), the auxiliary materials are 0.3-0.5 times of the mixed mass of the folic acid compounds, the ginkgo powder, the medlar powder and the lotus seed powder.
Compared with the prior art, the invention has the technical advantages that:
(1) the folic acid-containing product for relieving anxiety provided by the invention has the advantages of obvious anxiolytic effect, no toxic or side effect, good taste, suitability for modern people with high pressure and in an anxiety state to eat as leisure food, capability of effectively relieving anxiety of people and benefit for physical and mental health.
(2) The medlar has better functions of regulating immunity, resisting fatigue and reducing blood pressure, the lotus seed has better functions of nourishing heart and soothing nerves, and the medlar and the lotus seed can be effectively promoted to have the effects of resisting fatigue, nourishing heart and soothing nerves after the ginkgo leaf and folic acid compounds are added. Therefore, the folic acid compounds, the ginkgo leaves, the medlar and the lotus seeds have better synergistic effect-promoting effect.
(3) The addition amounts of the folic acid compounds and the ginkgo leaves in the invention have great influence on the effect of the product, and the anxiety relieving effect of the product can be effectively improved by reasonably selecting the use amounts of the folic acid compounds and the ginkgo leaves.
Detailed Description
The present invention will be described below with reference to specific examples to make the technical aspects of the present invention easier to understand and grasp, but the present invention is not limited thereto. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials are commercially available, unless otherwise specified.
Example 1
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0001 part of folic acid compound, 40 parts of ginkgo leaf, 20 parts of medlar and 25 parts of lotus seed.
The folic acid compound is leucovorin;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, sieving folium Ginkgo with 100 mesh sieve, and sieving fructus Lycii and semen Nelumbinis with 80 mesh sieve respectively to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.4 times of aspartame.
Example 2
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.001 part of folic acid, 5 parts of ginkgo leaf, 40 parts of medlar and 10 parts of lotus seed;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, sieving folium Ginkgo with 100 mesh sieve, and sieving fructus Lycii and semen Nelumbinis with 100 mesh sieve respectively to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.3 times of stevioside.
Example 3
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0003 part of folic acid compound, 25 parts of ginkgo leaf, 30 parts of medlar and 15 parts of lotus seed.
The folic acid compounds are L-methyl folic acid;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, sieving folium Ginkgo with 120 mesh sieve, and sieving fructus Lycii and semen Nelumbinis with 100 mesh sieve respectively to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.5 times of sucrose.
Example 4
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0003 part of folic acid compound, 25 parts of ginkgo leaf, 30 parts of medlar and 15 parts of lotus seed.
The folic acid compound is a mixture of leucovorin and L-methyl folic acid in a mass ratio of 3: 1;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, sieving folium Ginkgo with 120 mesh sieve, and sieving fructus Lycii and semen Nelumbinis with 100 mesh sieve respectively to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.5 times of sucrose.
Example 5
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0003 part of folic acid compound, 25 parts of ginkgo leaf, 30 parts of medlar and 15 parts of lotus seed.
The folic acid compound is a mixture of leucovorin and L-methyl folic acid in a mass ratio of 1: 1;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, sieving folium Ginkgo with 120 mesh sieve, and sieving fructus Lycii and semen Nelumbinis with 100 mesh sieve respectively to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.5 times of sucrose.
Comparative example 1
Compared with example 3, the difference is in the composition.
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0003 part of folic acid compound, 25 parts of ginkgo leaf, 30 parts of medlar and 15 parts of spina date seed.
The folic acid compounds are L-methyl folic acid;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Ziziphi Spinosae respectively, sieving folium Ginkgo with 120 mesh sieve, and sieving fructus Lycii and semen Ziziphi Spinosae respectively with 100 mesh sieve to obtain semen Ginkgo powder, fructus Lycii powder, and semen Ziziphi Spinosae powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Ziziphi Spinosae powder, and adding 0.5 times of sucrose.
Comparative example 2
Compared with example 3, the difference is in the composition.
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.1 part of folic acid compound, 25 parts of ginkgo leaf, 30 parts of medlar and 15 parts of lotus seed.
The folic acid compounds are L-methyl folic acid;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, sieving folium Ginkgo with 120 mesh sieve, and sieving fructus Lycii and semen Nelumbinis with 100 mesh sieve respectively to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.5 times of sucrose.
Comparative example 3
Compared with example 3, the difference is in the composition.
A product for relieving anxiety comprises the following components in parts by weight:
25 parts of ginkgo leaves, 30 parts of medlar and 15 parts of lotus seeds.
The preparation method of the product for relieving anxiety comprises the following steps:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, sieving folium Ginkgo with 120 mesh sieve, and sieving fructus Lycii and semen Nelumbinis with 100 mesh sieve respectively to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.5 times of sucrose.
Comparative example 4
Compared with example 3, the difference is in the composition.
In this example, the folic acid-containing anxiety-relieving product comprises the following components in parts by weight:
0.0003 part of folic acid compound, 30 parts of medlar and 15 parts of lotus seed.
The folic acid compounds are L-methyl folic acid;
a method for preparing folic acid-containing anxiety-relieving product comprises the following steps:
(1) pulverizing fructus Lycii and semen Nelumbinis respectively, and sieving with 100 mesh sieve to obtain fructus Lycii powder and semen Nelumbinis powder;
(2) mixing folic acid compounds, fructus Lycii powder, and semen Nelumbinis powder, and adding 0.5 times of sucrose.
Effect test
1. Mouse assay
With routine animal experiments demonstrating anxious depression: tail suspension test and forced swimming test.
Male mice of Kunming species weigh 18-22 g. The experimental environment temperature is 20-24 ℃, and the humidity is 50-60%. The mice freely ingest and drink water, the experiment is adapted for 5 days before the experiment, and the formal experiment is started after the examination is qualified.
The mice were randomly divided into 11 groups, which were a model group, a positive group, examples 1 to 5 of the present invention, and comparative examples 1 to 4, respectively; each group had 10. The feeding amount of the groups of examples 1 to 5 and comparative examples 1 to 4 is 0.5g/kg, the positive group is fluoxetine hydrochloride (dosage is 0.01g/kg), and the groups of examples, comparative examples and drugs are prepared into a suspension with physiological saline; the model group was injected with an equal dose of saline during the administration period. The preparation is administered by intragastric administration once a day 1 time per day for 14 days, and is tested after 2h of the last administration.
(1) Tail suspension test for mice
The tail suspension test of the mouse mainly comprises the steps that the head of the mouse is suspended downwards by fixing the tail of the mouse, the mouse is in a panic state in the environment and struggles to struggle to escape and cannot escape, an unavoidable compression environment is provided for the mouse, and after a period of time, the immobility time of the mouse in the environment in the process of generating an unexpected immobility state is recorded so as to observe the treatment effect after drug administration. The tail end of the mouse is stuck on a bracket at the upper part of the tail suspension box, and the tail suspension box is turned into an inverted suspension state to carry out tail suspension experiments. The head of the upside-down hanging mouse is 10cm away from the bottom of the box, 2 mice are hung at one time, and the middle of the upside-down hanging mouse is separated by a partition plate so as to avoid collision. The mouse can struggle after hanging upside down due to panic, and can be in disappointed state and be discontinuous and motionless after struggling and fatiguing. Suspending the mice for 10 minutes, and counting the cumulative immobile time of the mice hanging the tail upside down within 5 minutes. The results are shown in Table 1:
TABLE 1 mouse Tail suspension test
Note: p < 0.05 compared to model group; p < 0.01.
(2) Forced swimming test
Through placing the experimental mouse in the aquatic of a limitation, the mouse is struggled in this environment and is tried to flee and can't escape again, provides a no oppression environment that can avoid, and after a period of experiment, the mouse shows the immobility state of typical action despair state promptly, and the immobility time when the record mouse produced the immobility state of despair to the therapeutic effect after the observation was used medicine. The mice are put into a plastic swimming box with the length of 50cm, the width of 40cm and the height of 40cm for a forced swimming test, 10 minutes are counted after the mice are put into water, and the accumulated motionless time that the mice only have little limb movement but do not struggle and show rest and floating states within 5 minutes is recorded.
TABLE 2 forced swimming test of mice
Note: p < 0.05 compared to model group; p < 0.01.
As seen from tables 1-2, compared with the model group, the immobility time of tail suspension test and the immobility time of swimming test of the mice of the positive group and the mice of the examples 1-5 are both reduced remarkably, and have remarkable difference, which indicates that the examples 1-5 of the invention have obvious effect of relieving anxiety and depression symptoms; as can be seen from the experimental data of comparative examples 1 to 4, the components of the product for relieving anxiety in the present invention have a large influence on the effect of relieving anxiety.
2. Anxiety patient test
The relief of anxiety in individuals with symptoms of anxiety was tested.
The test subjects are the population between 20 and 50 years old, the gender and the occupation are not limited, and the self-statement shows obvious anxiety symptoms caused by long-term pain, sadness and anxiety after family disputes, emotional crisis or rupture, working and living pressure, sudden leaving of relatives and the like, and the symptoms last for more than 1 year. 10 persons per group; after 2 consecutive months, the patients with anxiety were counted for improvement of symptoms by taking the products of example 3 of the present invention and comparative examples 1 to 4 continuously. The test results are shown in table 3:
TABLE 3 improvement of symptoms in anxiety patients
Therefore, the product of the invention has obvious effect on relieving anxiety symptom, and the composition components of the product have important influence on the effect.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.
Claims (10)
1. A folic acid-containing product for relieving anxiety, which comprises the following components:
folic acid compounds, ginkgo leaves, medlar and lotus seeds.
2. The folate-containing product for relieving anxiety according to claim 1, wherein said folate compound is one or more of folic acid, leucovorin, L-methyl folic acid, a pharmaceutically acceptable salt of folic acid, an active metabolite of folic acid or a pharmaceutically acceptable salt of folic acid, and a substance that metabolizes and/or produces folic acid in vivo.
3. The folate-containing anxiety-relief product of claim 1, wherein said folate is a mixture of leucovorin and L-methylfolic acid.
4. The folic acid containing anxiety-relieving product of claim 1, comprising the following components in parts by weight:
0.0001-0.001 part of folic acid compound, 5-40 parts of ginkgo leaf, 20-40 parts of medlar and 10-25 parts of lotus seed.
5. The folic acid containing anxiety-relieving product of claim 1, comprising the following components in parts by weight: 0.0001-0.0006 part of folic acid compound, 25-40 parts of ginkgo leaf, 20-30 parts of medlar and 10-20 parts of lotus seed.
6. The folic acid containing anxiety-relieving product of claim 1, comprising the following components in parts by weight: 0.0001-0.0003 part of folic acid compound, 25-30 parts of ginkgo leaf, 25-30 parts of medlar and 10-15 parts of lotus seed.
7. A process for the preparation of a folate-containing anxiety-relieving product according to any one of claims 1 to 6, comprising the steps of:
(1) pulverizing folium Ginkgo, fructus Lycii, and semen Nelumbinis respectively, and sieving to obtain semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder;
(2) mixing folic acid compounds, semen Ginkgo powder, fructus Lycii powder, and semen Nelumbinis powder, and adding adjuvants.
8. The method for preparing the folic acid-containing product for relieving anxiety as defined in claim 7, wherein in the step (1), the sieving is carried out by sieving ginkgo leaves with a sieve of 100 meshes and 120 meshes, and the medlar and lotus seeds are respectively sieved with a sieve of 80 meshes to 100 meshes.
9. The method for preparing the folic acid-containing anxiety relieving product according to claim 7, wherein in the step (2), the auxiliary material is one or more of sucrose or xylitol, aspartame and stevioside.
10. The method for preparing the folic acid-containing anxiety relieving product according to claim 7, wherein in the step (2), the auxiliary materials are 0.3 to 0.5 times of the mixed mass of the folic acid compounds, the ginkgo biloba powder, the medlar powder and the lotus seed powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011329674.8A CN112546120B (en) | 2020-11-24 | 2020-11-24 | Product containing folic acid for relieving anxiety |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011329674.8A CN112546120B (en) | 2020-11-24 | 2020-11-24 | Product containing folic acid for relieving anxiety |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112546120A true CN112546120A (en) | 2021-03-26 |
| CN112546120B CN112546120B (en) | 2022-02-18 |
Family
ID=75043238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011329674.8A Active CN112546120B (en) | 2020-11-24 | 2020-11-24 | Product containing folic acid for relieving anxiety |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112546120B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114224919A (en) * | 2021-11-30 | 2022-03-25 | 北京斯利安健康科技有限公司 | Pharmaceutical composition for relieving depression and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110237204A (en) * | 2019-07-18 | 2019-09-17 | 北京斯利安药业有限公司 | It is a kind of with brain tonic/conditioning cranial nerve effect composition |
-
2020
- 2020-11-24 CN CN202011329674.8A patent/CN112546120B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110237204A (en) * | 2019-07-18 | 2019-09-17 | 北京斯利安药业有限公司 | It is a kind of with brain tonic/conditioning cranial nerve effect composition |
Non-Patent Citations (1)
| Title |
|---|
| 张丽娟等: "叶酸联合银杏叶片治疗老年阿尔茨海默病合并高同型半胱氨酸血症的疗效观察", 《中国老年学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114224919A (en) * | 2021-11-30 | 2022-03-25 | 北京斯利安健康科技有限公司 | Pharmaceutical composition for relieving depression and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112546120B (en) | 2022-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9603866B2 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN102845749B (en) | Health-care composition capable of improving sleep and aiding in improving memory | |
| BRPI0617988A2 (en) | anti-obesity composition, use of melissa extract, use of a mixture of melissa extract and mori folium extract, use of a mixture of melissa extract, artemisia extract and mori folium extract and method to suppress obesity | |
| JPH07507569A (en) | How to promote nitrogen retention in humans | |
| CN107581255A (en) | A kind of composition for improving sleep quality and preparation method thereof | |
| CN102160664A (en) | Nutritious drink for children | |
| CN110448654A (en) | It is a kind of to intervene the Chinese medicine composition of damp-heat constitution, broken wall composition and preparation method thereof | |
| CN106723021A (en) | A kind of functional food for improving the health care of sleep | |
| CN112546120B (en) | Product containing folic acid for relieving anxiety | |
| CN101606703A (en) | A kind of nutraceutical and preparation method thereof with antihypertensive function | |
| RU2423121C2 (en) | Preventive anti-stress medication | |
| CN106389740A (en) | Composition for preventing and/or delaying old people with mild cognitive impairment and use method thereof | |
| RU2333677C2 (en) | Dietary supplement | |
| CN105901145A (en) | Sleep comforting pasteurized milk and preparation method thereof | |
| CN103005439B (en) | Bitter gourd compound lipid-lowering oral solution and preparation method thereof | |
| CN111358961B (en) | Application of Tibetan medicine eighteen-ingredient myrobalan diuretic pill and test method of brain protection effect of Tibetan medicine eighteen-ingredient myrobalan diuretic pill on type 2 diabetic encephalopathy rats | |
| JPH1025246A (en) | Oral hypnotic agent, hypnotic beverage and food, and hypnotic feed | |
| CN112641100A (en) | Anti-depression electuary containing folic acid | |
| CN101254199A (en) | Panax saponin Rg1 and thein combination and uses thereof | |
| CN110384782A (en) | It is a kind of to intervene the Chinese medicine composition of phlegm-dampness constitution, broken wall composition and preparation method thereof | |
| Morton | The drug aspects of the white sapotes | |
| CN108785649B (en) | Composition for controlling weight of pressure type obesity | |
| CN104688724B (en) | Epimedium aglucone is preparing the application in anti-fatigue medicament | |
| Otimenyin et al. | Hypnotic effect of methanolic extracts of Annona senegalensis bark and Ficus thonningii leaves in mice and chicks | |
| Lennox | Antonius Guainerius on epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |